Metformin and GLP-1 receptor agonists significantly reduce asthma attacks in patients with type 2 diabetes, offering ...

蓝鲸新闻11月14日讯（记者 屠俊）随着饮食习惯与生活方式的变迁，中国的糖尿病患病率也迅速增加。根据国际糖尿病联盟（IDF）最新发布的数据表明，截至2021年，中国20-79岁人群中糖尿病的患病率为10.6%，患病人数达到了1.41亿，是世界上糖尿病患者最多的国家。

封面新闻记者 周家夷前不久，在上海举办的第七届中国国际进口博览会上，“马斯克同款”全球首个用于长期体重管理的GLP-1周制剂“诺和盈”引起不少关注。11月17日，这款用于长期体重管理的司美格鲁肽注射液正式在中国上市。与此前的“降糖版”司美格鲁肽注射液 ...

诺和盈是诺和诺德旗下的一款司美格鲁肽注射液，于今年6月获批用于国内患者的长期体重管理。作为全球首个且唯一一款用于长期体重管理的GLP-1受体激动剂类药物，在过去的5个月里，国内各大医药商业公司都在积极搭建诺和盈的供应链。

A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

An estimated one in ten Americans have been on a GLP-1. Some 12% — or about 1 in 8 — people living in the U.S. have tried a GLP-1 drug, according to a survey by the Kaiser Family Foundation. And with ...

Driving business growth through innovative food and nutrition strategies for CPG & foodservice brands. 💡 The Rise of GLP-1 ...

躺着就能减肥？需要医生评估后循序渐进用药减重版司美格鲁肽在沪开出首批处方全球首个用于长期体重管理的GLP-1RA周制剂用于长期体重管理的司美格鲁肽注射液这几天在上海开出首批处方，引发热议。

“The results of this cohort study suggest that metformin was associated with a lower rate of asthma attacks, with further reductions with the use of GLP-1 RA,” the authors write. “This appeared to be ...

The holidays are near, and so is the season of eating decadent meals – and sometimes, overeating. Overindulging on food is ...

As GLP-1 drugs like Ozempic soar in popularity for weight loss, this film follows three people on their own GLP-1 journeys and explores how decades of diet culture and society’s relentless pursuit of ...

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...